Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy

Yaguang Xi, MBA, MD, PhD
Amgen Oncology Professor and Vice Chair for Research, Department of Genetics
Location: Available by Zoom (Please see your SOM email announcement for the link)

For more information or program materials email Yaguang Xi, MBA, MD, PhD at yxi@lsuhsc.edu

CME Learning Objectives:

1. Understand the clinical challenges of treating colorectal cancer (CRC)
2. Understand the immunomodulatory role of sulindac in CRC
3. Understand the process of developing safer more efficacious CRC therapies

Accreditation: The Louisiana State University School of Medicine, New Orleans is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement: The Louisiana State University School of Medicine, New Orleans designates this live activity for a maximum 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.